Physician profile
Michael Haines
NPI 1518906346
$5,645.44
in general payments reported to CMS, 2019-2025
22 companies · $660 in 2025
The $660 reported for 2025 was more than what 84% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $519 · 2020: $2,144 · 2021: $372 · 2022: $893 · 2023: $800 · 2024: $257 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,698 · Entertainment: $18.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,698.14 |
| Entertainment | $18.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $2,322.36 | 2019-2024 | Myday Contact Lens, Biofinity Contact Lens |
| Alcon Vision LLC | $1,216.23 | 2019-2025 | Total30, Precision7, Dailies Total1 |
| Bausch & Lomb Americas INC. | $970.35 | 2022-2025 | Infuse |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $235.17 | 2019-2020 | |
| Optos, INC. | $130.32 | 2019-2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Tarsus Pharmaceuticals, INC. | $98.01 | 2025 | Xdemvy |
| Maculogix, INC. | $89.65 | 2019 | |
| Kala Pharmaceuticals, INC. | $88.73 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $80.73 | 2022-2023 | Acuvue |
| Apellis Pharmaceuticals, INC. | $66.04 | 2025 | Syfovre |
| Eyevance Pharmaceuticals LLC | $62.58 | 2021 | |
| Lkc Technologies, INC. | $49.32 | 2023 | |
| Allergan, INC. | $44.98 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $39.08 | 2019-2023 | Cequa |
| Mallinckrodt Hospital Products INC. | $37.50 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $29.46 | 2019-2021 | |
| Abbvie INC. | $24.89 | 2022 | |
| Shire North American Group INC | $20.80 | 2019 | |
| Dompe US, INC. | $16.48 | 2022 | |
| Ivantis, INC | $11.14 | 2020 | |
| Visioneering Technologies, INC. | $10.10 | 2019 | |
| Biotissue Holdings INC. | $1.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Haines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.